What is HC Wainwright’s Forecast for NRIX FY2026 Earnings?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Nurix Therapeutics in a report released on Friday, October 16th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($2.99) per share for the year, down from their previous forecast of ($2.91). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is $1.15 per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q4 2026 earnings at ($0.33) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.61) EPS and Q4 2027 earnings at ($0.64) EPS.

NRIX has been the topic of several other research reports. Truist Financial lowered their target price on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Royal Bank Of Canada cut their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating for the company in a report on Tuesday, October 13th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Finally, Robert W. Baird lifted their price objective on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.79.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $24.93 on Tuesday. The company has a market cap of $2.72 billion, a P/E ratio of 10.79 and a beta of 1.82. Nurix Therapeutics has a one year low of $9.93 and a one year high of $28.23. The firm has a fifty day moving average of $25.09 and a two-hundred day moving average of $21.27.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. The firm had revenue of $673.06 million for the quarter, compared to analyst estimates of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NRIX. Trails Edge Capital Partners LP acquired a new position in Nurix Therapeutics during the second quarter worth about $38,166,318. Bank of New York Mellon Corp acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at approximately $6,614,000. Man Group plc acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at approximately $2,076,000. Bank of America Corp DE acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at approximately $20,429,000. Finally, Perceptive Advisors LLC boosted its stake in shares of Nurix Therapeutics by 4.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock worth $57,519,000 after acquiring an additional 155,000 shares in the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other news, Director Julia P. Gregory sold 22,583 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the transaction, the director owned 10,750 shares in the company, valued at $251,550. This trade represents a 67.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gwenn Hansen sold 1,452 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $25.00, for a total transaction of $36,300.00. Following the completion of the transaction, the insider owned 117,227 shares of the company’s stock, valued at $2,930,675. This represents a 1.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 45,407 shares of company stock valued at $1,083,206. 6.70% of the stock is owned by company insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.